ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California. Show more
Location: 3530 John Hopkins Court, San Diego, CA, 92121, United States | Website: https://immunitybio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
2.24B
52 Wk Range
$1.83 - $7.48
Previous Close
$2.37
Open
$2.38
Volume
6,307,524
Day Range
$2.29 - $2.40
Enterprise Value
2.622B
Cash
153.7M
Avg Qtr Burn
-87.39M
Insider Ownership
69.20%
Institutional Own.
13.24%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Anktiva (N-803) + BCG Details Non-muscle invasive bladder cancer | Approved Update | |
ANKTIVA (N-803) + tislelizumab, 2L post-CPI Details Non-small cell lung carcinoma | Phase 2/3 Data readout | |
PD-L1 t-haNK Details Pancreatic cancer | Phase 2/3 Update | |
ANKTIVA + adenovirus vaccine Details Lynch Syndrome | Phase 2 Data readout | |
Phase 2 Data readout | ||
ANKTIVA Details Lymphopenia | Phase 2 Update | |
Anktiva (N-803) + AdHER2DC Details Endometrial cancer | Phase 1/2 Initiation | |
CAR-NK / CD19 t-haNK Details Non-Hodgkin lymphoma | Phase 1 Update | |
hAd5-COVID-19 Details Vaccine, COVID-19 | Failed Discontinued | |
N-803 (Anktiva), haNK and Avelumab Details Metastatic merkel cell carcinoma, Insomnia, Mood disorders, Liver transplant, Cancer | Failed Discontinued |